Related Experiment Video
Updated: Jan 31, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
Bioequivalence studies with anti-TNF biosimilars
Mercedes Gimeno-Gracia1, Carla J Gargallo-Puyuelo2, Fernando Gomollón3
1Service of Pharmacy, Hospital Clínico Universitario "Lozano Blesa", IIS Aragón , Zaragoza , Spain.
Biosimilars, including infliximab and adalimumab, demonstrate bioequivalence to originators. Switching from originator biologics to biosimilars is safe across all approved indications, according to current evidence.
Area of Science:
- Immunology
- Pharmacology
- Biotechnology
Background:
- Biosimilars have been utilized in Europe since 2006, with significant expansion following the introduction of monoclonal antibody biosimilars.
- The infliximab biosimilar CT-P13, approved in 2013, faced skepticism regarding bioequivalence due to the complex nature of these molecules.
- Numerous infliximab and adalimumab biosimilars are now available or expected soon, increasing the need for clinical evidence.
Purpose of the Study:
- To review the clinical evidence supporting the bioequivalence of anti-TNF biosimilars.
- To evaluate both preclinical and clinical data concerning biosimilar efficacy and safety.
- To provide an expert opinion on the current state of biosimilar adoption and future research needs.
Main Methods:
- Comprehensive review of preclinical studies submitted for regulatory approval.
- Analysis of clinical trial data assessing the efficacy and safety of anti-TNF biosimilars.
- Synthesis of expert opinions and published literature on biosimilarity.
Main Results:
- Bioequivalence of biosimilars to their originator counterparts is well-established for products following European Medicines Agency regulatory pathways.
- Clinical data indicate that switching from originator biologics to biosimilars is safe for all approved indications.
- Limited data exist regarding switching between different biosimilars or for complete interchangeability.
Conclusions:
- Anti-TNF biosimilars approved via EMA pathways are bioequivalent to originators.
- Switching from originator biologics to biosimilars is safe and recommended for all indications.
- Further prospective studies and robust pharmacovigilance are essential for evaluating switches between biosimilars and for interchangeability.
More Related Videos
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
07:51Effect of Anti-c-fms Antibody on Osteoclast Formation and Proliferation of Osteoclast Precursor In Vitro
Published on: March 18, 2019
Related Concept Videos
Bioequivalence studies: Biowaivers
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Bioequivalence: Overview
Drug Products: Biologics, Biosimilars and Interchangeables
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
Equivalence: In Vitro and In Vivo Bioequivalence